Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the use of temporarily idle raised funds by Hangzhou Anjiesi Medical Technology Co., Ltd. for cash management. It includes investment purpose, amount, sources, methods, risk analysis, and the sponsor's verification opinion. The document references compliance with regulatory rules and internal approvals but does not present financial statements or earnings data. It is a formal verification and opinion report related to the use of raised funds, not a financial report or earnings release. The document length is 4593 characters, which is substantial and contains detailed content, not just an announcement or certification. This fits the category of a Regulatory Filing (RNS) as it is a compliance and verification document related to fundraising and cash management, not a full financial report or announcement of voting results or capital changes.
2026-04-22 Chinese
安杰思关于2025年员工持股计划第二次持有人会议决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the resolutions of the second holders' meeting of the 2025 Employee Stock Ownership Plan. It details the meeting date, voting results, and decisions such as the failure to meet performance targets for unlocking shares and the termination and repurchase cancellation of the 2025 Employee Stock Ownership Plan. The content focuses on shareholder meeting resolutions related to employee stock plans rather than financial results, management changes, or regulatory filings. It is not a full report but an official announcement of meeting resolutions and voting outcomes related to the employee stock ownership plan. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1503 characters), but it contains detailed voting results and resolutions, not just a notice of report publication or a brief regulatory filing. Hence, it is not RPA or RNS.
2026-04-22 Chinese
安杰思第三届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 3rd Board of Directors of Hangzhou Anjiesi Medical Technology Co., Ltd. It includes approvals of various reports such as the 2025 Annual Report, 2026 Q1 Report, financial statements, audit reports, remuneration plans, and other corporate governance matters. The document repeatedly states that these reports and materials have been or will be disclosed separately on the Shanghai Stock Exchange website, indicating this document itself is not the full reports but a board meeting resolution announcement. The document is lengthy (over 10,000 characters) and contains detailed board meeting decisions, which fits the category of Board/Management Information (MANG). It is not a full annual report (10-K), audit report (AR), or earnings release (ER), but a comprehensive board meeting resolution announcement covering multiple governance and management topics. Therefore, the best classification is MANG with high confidence.
2026-04-22 Chinese
天健审〔2026〕8053号-安杰思2025年度关联方资金占用报告
Audit Report / Information Classification · 91% confidence The document is a special audit report (“专项审计说明”) on non-operating funds occupancy and related‐party transactions for the 2025 fiscal year. It contains the auditor’s engagement scope, responsibilities, audit procedures, and conclusion on a specific summary table, rather than the full annual report. This matches the definition of a standalone Audit Report (Code: AR). FY 2025
2026-04-22 Chinese
安杰思董事会对在任独立董事独立性自查情况的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the company's board regarding the independence of current independent directors, referencing regulatory requirements and self-assessment. It does not contain financial data, audit results, or detailed report content. It is a governance-related announcement about board members' independence compliance, fitting best under Board/Management Information (MANG). The document length is short and focused on management/board information rather than a full report or announcement of voting results.
2026-04-22 Chinese
安杰思董事、高级管理人员离职管理制度
Board/Management Information Classification · 95% confidence The document is titled '杭州安杰思医学科技股份有限公司 董事、高级管理人员离职管理制度' which translates to 'Hangzhou Anjiesi Medical Technology Co., Ltd. Board and Senior Management Personnel Resignation Management System.' The content details the rules, procedures, and obligations related to the resignation and departure of directors and senior management personnel. It includes sections on resignation conditions, handover procedures, obligations after departure, and accountability mechanisms. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, and no report publication announcements. The document is a governance-related internal policy about board and management personnel changes, specifically focusing on resignation management. This fits best under the category of Board/Management Information (MANG), which covers announcements or information about changes in the company's board or senior management. The document is not a brief announcement but a detailed policy document, so it is not a Regulatory Filing (RNS). Given the content and nature, the classification is MANG with high confidence.
2026-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.